| Literature DB >> 30901930 |
Constantin Mircioiu1, Victor Voicu2, Valentina Anuta3, Andra Tudose4, Christian Celia5, Donatella Paolino6, Massimo Fresta7, Roxana Sandulovici8, Ion Mircioiu9.
Abstract
Embedding of active substances in supramolecular systems has as the main goal to ensure the controlled release of the active ingredients. Whatever the final architecture or entrapment mechanism, modeling of release is challenging due to the moving boundary conditions and complex initial conditions. Despite huge diversity of formulations, diffusion phenomena are involved in practically all release processes. The approach in this paper starts, therefore, from mathematical methods for solving the diffusion equation in initial and boundary conditions, which are further connected with phenomenological conditions, simplified and idealized in order to lead to problems which can be analytically solved. Consequently, the release models are classified starting from the geometry of diffusion domain, initial conditions, and conditions on frontiers. Taking into account that practically all solutions of the models use the separation of variables method and integral transformation method, two specific applications of these methods are included. This paper suggests that "good modeling practice" of release kinetics consists essentially of identifying the most appropriate mathematical conditions corresponding to implied physicochemical phenomena. However, in most of the cases, models can be written but analytical solutions for these models cannot be obtained. Consequently, empiric models remain the first choice, and they receive an important place in the review.Entities:
Keywords: boundary conditions; diffusion equation; drug carriers; release kinetics
Year: 2019 PMID: 30901930 PMCID: PMC6471682 DOI: 10.3390/pharmaceutics11030140
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Spatial distribution of the active substance at different (t) time points.
Figure 2Release kinetics of a drug from microemulsions in an experiment using a dialysis membrane.
Figure 3Spatial distribution of the concentrations of active substance at different time intervals: (a) case , transfer into the membrane; (b) case , transfer out of the membrane.
Figure 4Distribution of concentration in a membrane separating two domains with constant concentrations.
Figure 5Radial transfer across a hollow sphere in a release medium where the concentration of drug has a constant value .
Figure 6Release of active substance embedded in liposomes.
Figure 7Higuchi’s moving boundary model inside solid and semisolid formulations.
Figure 8Higuchi’s model for release from a spherical tablet of radius R, in the condition of a moving solvent front.
Figure 9Swelling of a spherical polymer particle following the intrusion of solvent across the outer surface.
Figure 10Marginal-type erosion models.
Figure 11Black-box model of transfer (weighting) function, defined in the space of image functions obtained after the application of an integral transformation.
Examples of the application of empirical models in describing release kinetics from micro-sized polymeric carriers.
| Drug | Supramolecular System | Main Excipients | Release Experiment | Empirical Model | Reference |
|---|---|---|---|---|---|
| Cefpodoxime proxetil | Micro-balloons (hollow microspheres) | Hydroxypropylmethyl cellulose (HPMC) ethyl cellulose (EC) | Method (M): United States Pharmacopoeia (USP) paddle apparatus | Higher values of correlation coefficients were obtained in the case of Higuchi’s square root of time kinetic treatment; diffusion was the predominant mechanism of drug release. | [ |
| Nimodipine | Microparticles | PLGA | DM: 50/50 ( | Higuchi model | [ |
| Ethinyl estradiol (EE) Drospirenone (DRSP) | Microparticles | PLGA | M: dialysis sac method | EE release from PLGA microparticles was faster than DRSP release; EE release is assumed to be primarily controlled by drug diffusion. | [ |
| Sodium | Spray-dried microparticle | Poly(glycerol adipate- | DM: PBS, pH 7.4 ( | Higuchi model | [ |
| Levonorgestrel | Microparticles | PLGA; Methocel | DM: 0.9% sodium chloride + 0.5% sodium dodecyl sulfate | Release kinetics followed predominantly a zero-order release profile. | [ |
| Anastrozole | Microparticles | PLGA | M: modified dialysis method | An initial burst release phase was followed by a gradual release phase with good correlation coefficients for the Higuchi model. | [ |
| Centchroman | Microparticles | Glutaraldehyde Glyoxal | NA | A burst release of 29% centchroman within an initial period of 40 h was seen, and the remaining 70% was released in the next 60 h following zero-order release kinetics. | [ |
| 5-fluorouracil | Microspheres | Bovine serum albumin | M: dynamic dialysis | Attenuated burst release in comparison with uncoated microspheres. | [ |
| Methotrexate (MTX) | Microspheres | Chitosan | DM: PBS, pH 7.4 | Biphasic release (more prominent for MTX microspheres). | [ |
| Vitamin B12 | Microparticles | Bovine serum albumin (BSA) | M: dialysis technique | First stage: power law and Weibull equations. | [ |
| Aspirin | Microcapsules | Ethyl cellulose, | M: USP apparatus 2 | The best fit was the Higuchi model, indicating diffusion-controlled release. The | [ |
Examples of application of empirical models in describing release kinetics from nano-sized polymeric carriers.
| Drug | Supramolecular System | Main Excipients | Release Experiment | Empirical Model | Reference |
|---|---|---|---|---|---|
| Docetaxel | Nanoparticles | Chitosan | Method (M): dialysis sac method | Higuchi’s square-root and Korsmeyer–Peppas; 0.45 ≤ | [ |
| Ofloxacin | Nanoparticles | Carboxymethyl gum kondagogu; Chitosan | M: dialysis sac method | Higuchi model; ‘ | [ |
| Aceclofenac | Nanoparticles | Eudragit RL 100- | M: dialysis sac method | Higuchi model | [ |
| Ellagic Acid | Biodegradable nanoparticles | PLGA polycaprolactone (PCL) | M: dialysis technique | An initial burst release was followed by Higuchi’s square-root pattern in the case of PLGA and PCL nanoparticles. | [ |
| Estradiol | Nanoparticles | PLGA | M: dialysis technique | Zero order for low-molecular-weight nanoparticles; it was considered that degradation plays a dominant role and controls the release rate. High-molecular-weight nanoparticles showed the best fit into the Higuchi’s model. | [ |
| Doxorubicin | Nanoparticles | Gelatin cross-linked | DM: PBS pH 7.4 | A correlation between the quantity of released drug and swelling of the nanoparticles was established using a power-law model. | [ |
| Chloroquine phosphate | Nanoparticles | Gelatin | DM: PBS pH 7.4 and distilled water | Fick’s power law allowed establishing a correlation between the quantity of released drug and swelling of the nanoparticles. | [ |
| Indomethacin | Nanocapsules | Pluronic F127 | M: dialysis technique | The release pattern was found to follow a power-law model, with | [ |
| Tigecycline | Nanoparticles | Calcium phosphate (CP) | DM: physiological solution at 37 °C | The tigecycline content was released within a 35-day period. The in vitro data were best fitted with the Weibull model, and the release was defined as non-Fickian transport. | [ |
| Moxifloxacin | Nanosuspensions | PLGA | M: USP apparatus 1 | All formulations followed Korsemeyer–Peppas release kinetics with | [ |
Examples of experiments concerning release from liquid crystals, described by empirical models.
| Drug | Supramolecular System | Main Excipients | Release Experiment | Empirical Model | Reference |
|---|---|---|---|---|---|
| Alpha lipoic acid (ALA) | Cubosomes loaded gel | Glycerol monooleate (GMO) | M: USP Apparatus 5, paddle over disk assembly | Higuchi model | [ |
| Doxorubicin | Bicontinuous lipidic cubic phases (LCPs) | GMO | DM: pH 7.4 and pH 5.8 buffer | Higuchi model was | [ |
| Capsaicin | Cubic phase gels | GMO: propylene glycol (1,2-propanediol, PG): water | DM: isotonic phosphate buffered solution (PBS) | Release kinetics were determined to fit Higuchi’s square-root equation indicating that the release was under diffusion control. | [ |
| Salicylic acid | Cubic phase gels | GMO | M: USP app I | Release mechanism could be fitted to both Higuchi and first-order models. | [ |
| 2-pyrrolidone | In situ cubic phase forming monoglyceride drug delivery systems | Monoglyceride (GMO or glycerol monolinoleate) | DM: 0.1 M phosphate buffer, pH 7.4, with 0.1% sodium azide as preservative | The release of oligonucleotide from the fully swollen cubic phase matrix followed a diffusion-controlled release mechanism square-root Higuchi model in 24-h intervals for all formulations. | [ |
| Carbamazepine | Nanoemulsion | Castor oil; Lipophilic emulsifier (lecithin or polyoxyl 35 castor oil); Tween 80 | M: dialysis technique | Higuchi model best characterized the release profiles for the nanoemulsions and for the free drug, and drug release was described as a diffusion process based on Fick’s law. | [ |
| Microemulsions | - | NA | Higuchi model | [ |
Examples of experiments concerning release from solid lipid nanoparticles and lipid dosage forms, described by empirical models.
| Drug | Supramolecular System | Main Excipients | Release Experiment | Empirical Model | Reference |
|---|---|---|---|---|---|
| Etofenamate | Solid Lipid Nanoparticles (SLN) | Compritol 888 ATO Precirol ATO 5 | NA | Higuchi model for Compritol 888 ATO SLNs; | [ |
| Curcuminoids | SLN | Poloxamer 188 | M; vertical Franz diffusion cells | 25% burst release of the curcuminoids within 10 min followed by controlled release pattern following Higuchi’s square-root model for 12 h | [ |
| Bixin | SLN | Trimyristin | M: diffusion using Franz diffusion cells | The release was first-order diffusion-controlled. | [ |
| Gatifloxacin | SLN | Stearic acid (SA)/ Compritol/Gelucire | M: Automated transdermal diffusion cells | The release pattern was found to follow Korsmeyer–Peppas model ( | [ |